Cardiol Therapeutics Inc. (CRDL)
NASDAQ: CRDL · Real-Time Price · USD
1.315
+0.015 (1.15%)
May 21, 2026, 12:39 PM EDT - Market open
Cardiol Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
18
Market Cap
145.71M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 78.76K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurora Cannabis | 272.13M |
| Akebia Therapeutics | 232.40M |
| Organigram Global | 196.43M |
| Lifecore Biomedical | 129.46M |
| Anika Therapeutics | 116.26M |
| Assertio Holdings | 102.16M |
| SIGA Technologies | 93.78M |
| Journey Medical | 64.68M |
CRDL News
- 7 days ago - Cardiol Therapeutics to Participate in Fireside Chat at H.C. Wainwright 4th Annual BioConnect Investor Conference at the NASDAQ - PRNewsWire
- 9 days ago - Cardiol Therapeutics Registration statement: Q1 2026 - Filings
- 9 days ago - Cardiol Therapeutics Registration statement: Q1 2026 - Filings
- 13 days ago - Cardiol Therapeutics Slides: Corporate presentation - Filings
- 14 days ago - Cardiol Therapeutics' Phase II MAvERIC Results Accepted for Publication in the Journal of the American Heart Association - PRNewsWire
- 23 days ago - Cardiol Therapeutics (CRDL) Expands MAVERIC Trial with New Clinical Sites - GuruFocus
- 23 days ago - Cardiol Therapeutics expands U.S. MAVERIC Phase III trial network - TheFly
- 23 days ago - Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program - PRNewsWire